Table 1:
Select pooled baseline characteristics after propensity score matching *
| SGLT2 v DPP4 (Cohort 1) | SGLT2 v GLP1 (Cohort 2) | |||||
|---|---|---|---|---|---|---|
| SGLT2 (n=61,876) |
DPP4 (n=61,876) |
SD | SGLT2 (n=55,989) |
GLP1 (n=55,989) |
SD | |
| Male, n (%) | 33,502 (54.1) | 33,645 (54.4) | 0.5 | 27,686 (49.4) | 27,715 (49.5) | 0.1 |
| Age, mean (SD) | 54.7 (9.9) | 54.7 (10.2) | 0.2 | 54.5 (10.1) | 54.4 (10.1) | 1.4 |
| Diabetic severity, n (%) | ||||||
| Ocular complications | 2,469 (4.0) | 2,453 (4.0) | 0.1 | 2,519 (4.5) | 2,466 (4.4) | 0.5 |
| Neurological complications | 4,567 (7.4) | 4,634 (7.5) | 0.4 | 5,126 (9.2) | 5,093 (9.1) | 0.2 |
| Other or unspecified complications | 4,292 (6.9) | 4,235 (6.8) | 0.4 | 4,381 (7.8) | 4,392 (7.8) | 0.1 |
| A1c, mean (SD)† | 8.8 (1.8) | 8.8 (1.9) | 0.1 | 8.7 (1.8) | 8.8 (1.9) | 0.1 |
| Antidiabetic therapy, n (%) | ||||||
| Metformin | 48,319 (78.1) | 48,480 (78.4) | 0.6 | 42,599 (76.1) | 42,586 (76.1) | 0.1 |
| Dipeptidyl peptidase-4 inhibitors | 17,046 (30.4) | 17,113 (30.6) | 0.3 | |||
| Glucagon-like peptide agonists | 4,915 (7.9) | 4,270 (6.9) | 4.0 | |||
| Insulin | 12,067 (19.5) | 11,838 (19.1) | 0.9 | 18,237 (32.6) | 18,117 (32.4) | 0.5 |
| Sulfonylureas | 22,052 (35.6) | 22,208 (35.9) | 0.5 | 20,850 (37.2) | 20,720 (37.0) | 0.5 |
| Risk factors for UTI, n (%) | ||||||
| Broad spectrum Antibiotic | 14,487 (23.4) | 14,393 (23.3) | 0.4 | 13,648 (24.4) | 13,489 (24.1) | 0.7 |
| Oral Steroids | 6,353 (10.3) | 6,263 (10.1) | 0.5 | 5,796 (10.4) | 5,833 (10.4) | 0.2 |
| DMARDs, non-biologic | 519 (0.8) | 509 (0.8) | 0.2 | 473 (0.8) | 481 (0.9) | 0.2 |
| DMARDS, biologic | 381 (0.6) | 389 (0.6) | 0.2 | 386 (0.7) | 391 (0.7) | 0.1 |
| Mycotic infections | 3,402 (5.5) | 3,377 (5.5) | 0.2 | 3,453 (6.2) | 3,439 (6.1) | 0.1 |
| Propensity Score diagnostics | ||||||
| AUC, Clinformatics | 0.52 | 0.51 | ||||
| AUC, MarketScan | 0.52 | 0.51 | ||||
| Average Standardized difference | 0.4% | 0.3% | ||||
Abbreviations: AUC: Area Under the Curve; DPP4: Dipeptidyl peptidase-4 inhibitors; GLP1: Glucagon-like peptide 1 agonists SD: Standardized differences; SGLT2: Sodium Glucose Cotransporter-2 inhibitors
*
Data Select pooled variables are shown; see Appendix Tables 3-6 for baseline characteristics prior to and after propensity score matching, stratified by database and cohort. See Appendix Table 7 for the analogous table for Table 1 prior to propensity score matching.
†
A1c laboratory data was available for 10% of the pooled sample and not included in the propensity score model